ENDRA reports Q3 net loss of $1.5m as Noble Africa merger awaits closing conditions
The liver-fat imaging developer says merger-related fees lifted G&A costs while R&D spending fell, with the proposed deal with an ASP Isotopes subsidiary still pending approvals.
16 Nov 2026 · ENDRA Life Sciences Inc. NDRA · Company news
ENDRA Life Sciences reported a net loss of $1.5 million for the third quarter of 2026 on 16 November, narrowing from $1.6 million in the same period a year earlier.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): ENDRA Life Sciences Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More Deals & M&AAll →
Deals & M&A
Gedeon Richter to acquire Mayne Pharma in AUD 604 million cash deal
16 Nov 2026 · Gedeon Richter · Company news
Deals & M&A
Aytu BioPharma to be acquired by Rosemont for about $56M as EXXUA sales grow
16 Nov 2026 · Aytu Biopharma, Inc AYTU · Company news
Deals & M&A
Merck KGaA to acquire Rapid Micro Biosystems in $0.75-per-share cash tender offer
16 Nov 2026 · Rapid Micro Biosystems, Inc. RPID · Company news
Deals & M&A
Jasper Therapeutics completes IgAN cohort enrolment as Kira deal closes and cash reaches $135.3M
16 Nov 2026 · Jasper Therapeutics, Inc. JSPR · Company news
Deals & M&A
MacroGenics reports $288M cash and 2028 runway, putting B7-H3 ADC MGC026 in head and neck cancer first
13 Nov 2026 · Macrogenics Inc MGNX · Company news
Deals & M&A
Xenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient
13 Nov 2026 · Xenetic Biosciences, Inc. XBIO · Company news